AMDCP Credit Designation: This session has been approved for a total of 2 Clinical credit hours toward certification as a Certified Medical Director in Long Term Care (CMD).
The American Medical Directors Association designates this educational activity fora maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Presenter(s): Barbara J. Messinger-Rapport, MD, PhD, CMD (Moderator); Ilo Leppik, MD; Daniel Bluestein,MD, MS, CMD; Margaret Baumgarten, MD; Thomas Lynch, PharmD; William N. Hovland,MD, CMD; Frank Palermo, MD, MPH Disclosure(s): Frank Palermo, MD, MPH is the medical director at Accelerated Care Plus. Barbara J. Messinger-Rapport, MD, PhD, CMD received speaker honoraria from Forest Pharmaceuticals, Inc. and Novartis. Products made by these companies related to this topic: Reclase and Namenda. Ilo Leppik, MDreceived a consulting fee from Sierra Neurosciences and Caremark, a speaker honorarium from Eisai Pharmaceuticals, and a research grant from UCB Pharma.
All other presenters reported they had no relevant financial relationships to disclose. Session Description: This session offers pearls on a variety of clinical topics. From learning how to differentiate between epileptic and non-epileptic seizures, and identifying the best anti-epileptic drug for an individual patient; to the epidemiology,assessment and complications of chronic kidney disease (CKD); to lastly, bladder physiology, including an explanation of the regulatory requirements for bladder retraining. Q&A time is allotted at the end of each clinical pearl. Learning Objectives:
Recognize epileptic seizures from non-epileptic seizures and order the appropriate tests for diagnosis
Define the properties of various anti-epileptic drugs and explain the use of anti-epileptic drug levels
Review the scope and consequences of CKD in long term care
Examine strategies for CKD assessment and management including prevention of complications
Comprehend the variants of urinary incontinence through bladder physiology and testing
References: Birnbaum A, Hardie NA, Leppik IE, et al. Variability of totalphenytoin serum concentrations within elderly nursing home residents. Neurology2003;60:555-559. Birnbaum AK, Hardie NA, Conway JM,Bowers SE, Lackner TE, Graves NM, Leppik IE. Valproic acid doses,concentrations, and clearances in elderly nursing home residents. EpilepsyResearch 2004:62:157-162. Bourdet SV, Gidal BE, Alldredge BK. Pharmacologic managementof epilepsy in the elderly. J Am Pharm Assoc (Wash). 2001 May-Jun;41(3):421-36. Cloyd, J. C., Lackner, T. E., and Leppik, I.E. (1994). Antiepileptics in the elderly. Pharmacoepidemiology andpharmacokinetics. Arch Fam Med 3, 589-598. Cramer JA, Leppik IE, DeRue K, Edrich P, Kramer G.Tolerability of levetiracetam in elderly patients with CNS disorders. EpilepsyResearch 2003:56:135-145. Cusack BJ. Drug metabolism in the elderly. J Clin Pharmacol.1988;28:571-576. Dong X, Leppik IE, White J, Rarick J. Hyponatremia fromoxcarbazepine and carbamazepine . Neurology 2005;65(12):1976-1978. Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, LeeP, Engel J Jr. Epileptic Seizures And Epilepsy: Definitions proposed by TheInternational League Against Epilepsy (ILAE) and the International Bureau ForEpilepsy (IBE). Epilepsia 2005;46:470-472. Garrard, J., Cloyd, J., Gross, C, Hardie, N, Thomas, L,Lackner, T, Graves,N, and Leppik, I. (2000).Factors associated with antiepileptic drug use among elderly nursing homeresidents. J Gerontol A Biol Sci Med Sci 55, M384-M392. Garrard J, Harms S, Hardie N, et al. Antiepileptic drug usein nursing home admissions. Ann Neurol 2003;54:75-85. Hauser WA. Seizure disorders: Thechanges with age. Epilepsia 1992;33 (Suppl 4):S6-S14.